The pentoxifylline experience: Exercise testing reconsidered

Vascular Medicine

Volumn 1, Issue 2, 1996, Pages 145-154

  Lindgarde F ^a   Labs, K H ^b   Roßner M ^b  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

^b SANOFI   (France)

Author keywords

clinical trial endpoints; COAD; pentoxifylline; responder population; spontaneous claudication distance improvement; treadmill testing

Indexed keywords

PENTOXIFYLLINE; PLACEBO;

CLINICAL FEATURE; CLINICAL PROTOCOL; DIAGNOSTIC ACCURACY; HUMAN; INTERMITTENT CLAUDICATION; PERIPHERAL OCCLUSIVE ARTERY DISEASE; PRIORITY JOURNAL; REVIEW; TREADMILL EXERCISE; ARTICLE; CLINICAL TRIAL (TOPIC); DISEASE CLASSIFICATION; EUROPEAN UNION; EXERCISE TEST; HEMODYNAMIC PARAMETERS; INTENTION TO TREAT ANALYSIS; PRACTICE GUIDELINE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCANDINAVIA; TREADMILL TEST; TREATMENT RESPONSE; UNITED STATES;

EID: 0029767046     PISSN: 1358863X     EISSN: None     Source Type: Journal    
DOI: 10.1177/1358863X9600100211     Document Type: Review

References (54)

1. De Backer G, Kornitzer M, Sobolski J, Denolin H. Intermittent claudication epidemiology and natural history. Acta Cardiol 1979; XXXIV: 115-24.
2. Criqui MH, Fronek A, Klauber MR, Barret-Conner E, Gabriel S. The sensitivity, specificity and predictive value of traditional clinical evaluation of peripheral arterial disease. Results from a non-invasive testing in a defined population. Circulation 1985; 71: 516-21.
3. Criqui MH, Langer RD, Fronek A et al. Mortality over a period of 10 years in patients with peripheral arterial disease. New Engl J Med 1992; 326: 381-86.
4. Gofin R, Kark JD, Friedländer Y et al. Peripheral vascular disease in a middle-aged population sample. Israel J Med Sci 1987; 23: 157-67.
5. Ruckley CV. Symptomatic and asymptomatic disease. In: Fowkes FOR, ed. Epidemiology of peripheral vascular disease. Heidelberg: Springer-Verlag, 1991: 97-108.
6. Vogt MT, Cauley JA, Kuller LH, Hulley SB. Prevalence and correlates of lower extremity arterial disease in women. Am J Epidemiol 1993; 137: 559-68.
7. Cronenwett JL, Warner KG, Zelenock GB et al. Intermittent claudication. Current results of nonoperative management. Arch Surg 1984; 119: 430-36.
8. Dormandy J, Mahir M, Ascady G et al. Fate of the patient with chronic leg ischaemia. J Cardiovasc Surg 1989; 30(suppl 1): 50-57.
9. European Working Group on Critical Limb Ischemia. Second European Consensus Document on Chronic Critical Limb Ischemia. Circulation 1991; 84 (suppl IV): IV-1-IV-26.
10. Jeines R, Gaardsting O, Hougaard Jensen K, Baekgaard N, Toennesen KH, Schroeder T. Fate in intermittent claudication: outcome and risk factors. Br Med J 1986; 293: 1137-40.
11. Naschitz JE, Ambrosio DA, Chang JB. Intermittent claudication: predictors and outcome. Angiology 1988; 39: 16-22.
12. Rosenbloom MS, Flanigan DP, Schuler JJ et al. Risk factors affecting the natural history of intermittent claudication. Arch Surg 1988; 123: 867-70.
13. Widmer LK, Stähelin HB, Nissen C, da Silva A. Venen-, Arterien Krankheiten, koronare Herzkrankheit bei Berufstätigen. Prospektiv-epidemiologische Untersuchung. Basler Studie I-III, 1959-1978. Bern: Hans Huber Verlag, 1981.
14. Dawson I, van Bockel JH, Brand R. Late nonfatal and fatal cardiac events after infrainguinal bypass for femoropopliteal occlusive disease during a thirtyone-year period. J Vasc Surg 1993; 18: 249-60.
15. Dawson I, van Bockel JH, Ferrari MD, van der Meer FJM, Brand R, Terpstra JL. Ischemic and hemorrhagic stroke in patients on oral anticoagulants after reconstruction for chronic lower limb ischemia. Stroke 1993; 24: 1655-63.
16. Diener HC, Seboldt H, Dichgans J, Andris M, Springer G, Baiker R. Stenosen und Verschlüsse der extrakraniellen Arterien. Feldstudie an unausgewählten Personen und bei Patienten mit Claudicatio intermittens. Dtsch Med Wochenschr 1983; 108: 496-500.
17. Hertzer NR. Fatal myocardial infarction following peripheral vascular operations. Cleve Clin Q 1982; 49: 1-11.
18. Hertzer NR, Beven EG, Young JR et al. Coronary artery disease in peripheral vascular patients. A classification of 1000 coronary angiograms and results of surgical management. Ann Surg 1984; 4: 223-33.
19. Janson R, Neuhaus G, Thelen M. Extrakranielle arterielle Verschlubßerkrankung bei gefäßchirurgischen Patienten mit peripheren Durchblutungsstörungen. Fortschr Röntgenstr 1980; 133: 484-93.
20. Janzon L, Bergqvist D, Boberg J et al. Prevention of myocardial infarction and stroke in patients with intermittent claudication; effects of ticlopedine. Results from STIMS, the Swedisch Ticlopedine Multicentre Study. J Intern Med 1990; 227: 301-308.
21. Sieben U, Müller-Bühl U, Berger B, Mörl H, Schuler G, Diehm C. Arterielle Verschlußkrankheit und koronare Herzkrankheit - gemeinsame Prävalenz und Risikofaktoren. VASA 1987; 20(suppl): 264-65.
22. Stavenow L, Karlsson S, Llija B, Lindgärde F. High prevalence of coronary heart disease in patients with intermittent claudication. Acta Chir Scand 1988; 154: 447-51.
23. Steinke W, AI-Deeb S, Hennerici M. Prävalenz extrakranieller Gefässprozesse und Risikoprofil bei Patienten mit peripherer und koronarer Arteriopathie. VASA 1987; 16: 283-90.
24. Szilagyi DE, Hageman JH, Smith RF, Elliott JP, Brown F, Dietz P. Autogeneous vein grafting in femoropopliteal atherosclerosis: the limits of its effectiveness. Surgery 1979; 86: 836-49.
25. Turnipseed WD, Berkoff HA, Beizer FO. Postoperative stroke in cardiac and peripheral vascular disease. Ann Surg 1980; 192: 365-68.
26. Vecht RJ, Nicolaides AN, Brandao E et al. Resting and electrocardio-graphic findings in patients with intermittent claudication. Int Angiol 1982; 1: 119-21.
27. Widmer LK, da Silva A, Widmer M-T. Epidemiologie und sozialmedizinische Bedeutung der peripheren arteriellen Verschlußkrankheit. In: Alexander K, ed. Gefäßkrankheiten. Munich: Urban and Schwarzenberg, 1994: 21.
28. O'Riordan DS, O'Donnell JA. Realistic expectations for the patient with intermittent claudication. Br J Surg 1991; 78: 861-63.
29. Jäger KA, Labs KH, FitzGerald DE, Labs R. Epidemiology, risk and hemodynamics. In: Labs KH, Schmid-Schönbein GW, Schönharting MM, eds. Leukocytes and endothelial interaction: pentoxifylline in peripheral vascular disease. Barcelona: Prous Science Publishers (in press).
30. Källerö KS, Bergqvist D, Cederholm C, Jonsson K, Olsson P-O, Takolander R. Late mortality and morbidity after arterial reconstruction: the influence of arteriosclerosis in popliteal artery trifurcation. J Vasc Surg 1985; 2: 541-46.
31. Mills JL, Brandyk LF. Surgical management of femoro-popliteal occlusive disease. In: Strandness DE, Van Breda A, eds. Vascular diseases: surgical and interventional therapy. New York: Churchill Livingstone, 1994: 493-99.
32. Efficacy Working Party of the Committee for Proprietary Medicinal Products. Note for guidance: guidelines for the clinical investigations of medical products in the treatment of chronic peripheral arterial occlusive disease. Brussels: December 1994.
33. Labs KH, Schüler A, Pischel T. Reproducibility of walking test results under constant treadmill conditions. Unpublished data.
34. Bollinger A. Funktionelle Angiologie. Lehrbuch und Atlas. Stuttgart: Georg Thieme, 1979: 18-20, 70-71.
35. Heidrich H. Vasoactive Pharmaka bei peripheren arteriellen Durchblutungsstörungen. Probleme, Prinzipien und Ergebnisse des therapeut-ischen Wirksamkeitsnachweises. Disch Med Wochenschr 1985; 110: 1219-24.
36. Weidinger P, Bachl N. 5 Jahre Wiener Erfahrungen mit amulanten Claudicatiogruppen. In: Diehm C, Gerlach HE, eds. Bewegungstherapie bei peripheren arteriellen Durchblutungsstörungen. Munich: Zuckschwerdt, 1987: 16-27.
37. Blair SN, Gibbons LW, Painter P, Pate RR, Barr Raylor C, Will J. Guidelines for exercise testing and prescription, third edition. Philadelphia: Lea and Febiger, 1986: 157-72.
38. Hammarsten J, Bylund-Fellenius A-C, Holm J, Schersten T, Krotkiewski M. Capillary supply and muscle fibre types in patients with intermittent claudication: relationships between morphology and metabolism. Eur J Clin Invest 1980; 10: 301-305.
39. 31P nuclear magnetic resonance spectroscopy. Clin Sci 1986; 71: 283-90.
40. Maass U, Grote R, Alexander K. Belastungsabhängige Stoffwechseländerungen bei Verschlusskranken mit unterschiedlicher schmerzfreier Gehstrecke. VASA 1986; 15: 206-11.
41. Maass U, Grote R, Alexander K. Belastungsabhzängige Stoffwechseländerungen bei arterieller Verschlusskrankheit mit unterschiedlicher Verschlusslokalisation. VASA 1986; 15: 212-16.
42. 31P nuclear magnetic resonance study. Mol Biol Med 1983; 1: 77-94.
43. Taylor DJ, Crowe M, Bore PJ, Styles P, Arnold DL, Radda GK. Examination of the energetics of aging skeletal muscle using nuclear magnetic resonance. Gerontology 1984; 30: 2-7.
44. Jäger KA, Labs KH. Unpublished results.
45. Gillings D, Koch G, Reich T, Stager WJ. Another look at the pentoxifylline efficacy data for intermittent claudication. J Clin Pharmacol 1987; 27: 601-609.
46. Hoechst Clinical Trial Database. Data on file.
47. Lindgärde F, Jelnes R, Björkman H et al. Conservative drug treatment in patients with moderately severe chronic occlusive peripheral arterial disease. Circulation 1989; 80: 1459-556.
48. Porter JM, Cutler BS, Lee BY et al. Pentoxifylline efficacy in the treatment of intermittent claudication. Multicenter controlled double-blind trial with objective assessment of chronic occlusive arterial disease patients. Am Heart J 1982; 104: 66-72.
49. Labs KH. Personal communications.
50. Accetto B. Beneficial hemorheologic therapy of chronic peripheral arterial disorders with pentoxifylline: results of double-blind study versus vasodilator-nylidrin. Am Heart J 1982; 103: 864-69.
51. Bollinger A, Frei Ch. Double-blind study of pentoxifylline against placebo in patients with intermittent claudication. Pharmatherapeutica 1977; 1: 557-62.
52. Kiesewetter H, Blume J, Jung F, Gerhards M, Leipnitz G. Gehtraining und medikamentöse Therapie bei der peripheren arteriellen Verschluß krankheit. Randomisierte, prospektive, placebo-kontrollierte Doppel-blindstudie. Dtsch Med Wochenschr 1987; 112: 873-78.
53. Kiesewetter H, Blume J, Jung F, Waldhausen P, Gerhards M. Claudicatio intermittens. Steigerung der Gehleistung und Besserung rheologischer Parameter durch Pentoxifyllin (Trental 400). Munch Med Wachenschr 1988; 130: 357-60.
54. Rudofsky G, Haussler KF, KUnkel HP et al. Zur intravenösen Pentoxifyllin-Behandlung der chronischen peripheren arteriellen Verschluß krankheit. Medwelt 1988; 39: 1136-40.